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Abstract
Bone and joint infections are becoming increasingly commonBackground: 
and are usually treated with surgery and a course of intravenous antibiotics.
However, there is no evidence to support the superiority of intravenous
therapy and there is a growing body of literature showing that oral therapy is
effective in treating these infections.Given this lack of evidence the clinical
trial ‘Oral Versus Intravenous Antibiotics’ (OVIVA) was designed to assess
the clinical and cost-effectiveness of intravenous versus oral antibiotics for
the treatment of bone and joint infections, using a non-inferiority design.
Clinical results from the trial indicate that oral antibiotics are non-inferior to
intravenous antibiotics. The aim of this paper is to evaluate the
cost-effectiveness of intravenous compared to oral antibiotics for treating
bone and joint infections, using data from OVIVA.
A cost-utility analysis was carried out, the main economicMethods: 
outcome measure was the quality adjusted life-year, measured using the
EQ-5D-3L questionnaire, combined with costs to estimate
cost-effectiveness over 12-months follow-up.
Results show that costs were significantly lower in the oral armResults: 
compared to the intravenous arm, a difference of £2,740 (95% confidence
interval £1,488 to £3,992). Results of four sensitivity analyses were
consistent with the base-case results. QALYs were marginally higher in the
oral arm, however this difference was not statistically significant; -0.007
(95% confidence interval -0.045 to 0.031).
Treating patients with bone and joint infections for the firstConclusions: 
six weeks of therapy with oral antibiotics is both less costly and does not
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 six weeks of therapy with oral antibiotics is both less costly and does not
result in detectable differences in quality of life compared to treatment with
intravenous antibiotics. Adopting a practice of treating bone and joint
infections with oral antibiotics early in the course of therapy could
potentially save the UK National Health Service over £17 million annually.
Keywords
antibiotics, oral, intravenous, cost-effectiveness, non-inferiority, economic
evaluation
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Introduction
Bone and joint infections are becoming increasingly common. 
In the UK, the National Health Service (NHS) conducts around 
190,000 hip and knee replacement surgeries annually; of these, 
approximately 1% will result in post-operative infections1,2. 
In addition, there are around 70,000 neck of femur fractures, 
surgery for which is associated with post-operative infection in 
up to 2.5% of cases, and 20,000 metalware or fracture-fixations 
with around a 15% infection rate (Personal communication, 
Dr M. Scarborough). There are also approximately 5,000 
diabetic foot infections and a smaller number of infections of 
the axial skeleton annually. Treatment for these infections is 
estimated to cost around £20,000 to £40,000 per patient3–5.
These infections are usually treated with surgery and an ini-
tial course of intravenous antibiotics for 4–6 weeks. However, 
there is no evidence to support the superiority of intravenous 
therapy and, in recent years, there has been a growing body of 
literature showing that oral therapy is effective in treating these 
infections. A Cochrane review in 20136 found there was no 
benefit of intravenous compared to oral antibiotics in treating 
bone and joint infection. The authors judged the trials to be of 
moderate to high risk of bias and there was no statistically sig-
nificant difference in the pooled results. Furthermore, most of the 
trials were conducted over 20 years ago, when there was a lower 
prevalence of bone and joint infections. The authors concluded 
that there was insufficient evidence from this review to inform a 
change in practice and there was a need for a randomised 
controlled trial to investigate this further.
Intravenous treatment requires an access device to administer 
the antibiotic which carries risk of infection and thromboembolic 
disease. Oral antibiotics do not carry these risks, are less costly 
and more convenient. However, oral antibiotics have a higher 
risk of non-adherence and gastro-intestinal intolerance7.
Given the lack of evidence on the superiority of intravenous com-
pared to oral antibiotics, the clinical trial “OVIVA” was designed 
to assess the treatment failure rate and cost-effectiveness of 
intravenous versus oral antibiotics for the first six weeks treat-
ment of bone and joint infections. The study directly tested the 
different antibiotic administration routes via a non-inferiority 
design set with a margin of 7.5 percentage points above the upper 
90% confidence interval around the risk difference. Clinical 
results from the trial indicate that oral antibiotics are non-inferior 
to intravenous antibiotics. The primary clinical outcome of treat-
ment failure (infection present) occurred in 74 of 506 participants 
(14.6%) in the intravenous arm and in 67 of 509 participants 
(13.2%) in the oral arm8.
This paper reports on the within-trial cost-effectiveness of 
OVIVA, estimating cost and quality-adjusted life year (QALY) 
differentials comparing intravenous antibiotics to oral antibiotics 
for the first six weeks of treatment of bone and joint infections.
Methods
Overview of analysis
OVIVA was a UK based multi-centre, open-label, randomised, 
controlled non-inferiority trial with 12 months follow-up. 
Participants were adults (18+ years) who, in the attending clini-
cian’s opinion, would normally be treated with a 6 weeks course 
of intravenous antibiotics for bone or joint infection. Participants 
started their randomised treatment within 7 days of surgery, 
or if no surgery for treatment of bone and joint infection, within 
7 days of starting antibiotics. Participants were randomised to 
either intravenous or oral antibiotics for the first 6 weeks of 
therapy. In the intravenous arm, where it was common practice 
for adjunctive oral agents to be used alongside intravenous agents 
this was allowed. In the oral arm, if intravenous antibiotic 
treatment was needed for an unrelated illness, this was allowed 
for up to five days. Follow-on antibiotic treatment using either 
route of administration was allowed in both arms. Participants 
were recruited between June 2010 and October 2015. The pri-
mary endpoint was definite failure of infection treatment 
(infection present) within 12 months of randomisation. Treatment 
failure was identified locally by the treating clinician and cat-
egorised by a blinded end-point committee as: definite, probable 
and possible. The non-inferiority margin was set at 7.5%, and 
non-inferiority was met if the upper limit of the 90% CI around 
the absolute risk difference between the arms fell below this 
margin. Mortality was not necessarily considered a treatment 
failure in the absence of meeting criteria for a primary endpoint 
and was included in the secondary endpoint of ‘serious adverse 
events’. Full methodological details of the trial are available in 
the published protocol7.
Individual patient data from the OVIVA trial were used to 
perform the cost-effectiveness analysis. Outcomes were meas-
ured in terms of QALYs. The analysis had a time horizon of 
12 months and an NHS and personal social services perspective, 
reported in GBP sterling (2015 GBP). No discounting was 
needed due to the short time horizon. Best practice guidance was 
followed for conducting and reporting the analysis9,10. Cost- 
effectiveness was judged using incremental costs per health out-
come measured against the current NICE threshold of £20,000 
to £30,000. Missing resource and quality of life data was 
imputed using multiple imputation by chained equation11 for the 
base case analysis and sensitivity analyses included a complete 
case analysis to explore the effect of excluding participants with 
missing data on the final results. Analysis was carried out in 
Stata 14.0 (StataCorp, College Station, TX, USA).
Resource use
Resource use data were collected using self-reported question-
naires completed at 42, 120- and 365-days post randomisation. 
Resource use groups comprised: antibiotic medication, intrave-
nous administration and inpatient stays. Antibiotic resource use 
included all antibiotics prescribed to each participant in the 
12-month follow-up period. Inpatient stays were measured in 
bed days and intravenous administration included the cost of 
intravenous line insertion and removal for each intravenous epi-
sode per participant, cost of line complications where a new 
line is needed, and the cost of the Outpatient Parenteral 
Antimicrobial Therapy (OPAT) team if applicable.
Unit costs for antibiotic medication were obtained from the 
British National Formulary12. Inpatient stays were valued using 
NHS reference costs13 and intravenous administration resources 
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and costs were taken from the literature14 and expert opinion 
(Personal communication, Dr M. Scarborough). Costs were 
adjusted for inflation using the Hospital and Community 
Health Index15. Unit costs and their sources are presented in 
Table 1.
Total costs per participant were calculated by assigning unit 
costs to within trial resource use for each participant.
Health outcomes
The economic outcome was the QALY, a measure combining 
both quality and length of life. Quality of life data were 
collected using the EQ-5D-3L questionnaire16, administered at 
baseline, 14 days, 42 days, 120 days, 365 days. EQ-5D-3L 
responses were valued using a UK tariff17. Standard area-under- 
the-curve methods were used to calculate QALYs18, which 
were adjusted for baseline utility19.
Missing data
Excluding participants with missing data can lead to loss of 
power and biased results because of a reduced sample size20. 
Because of this, the nature of the missing data was analysed and 
an appropriate method to replace missing data utilised9,21. Base- 
case data had missing resource and quality of life data; these 
missing data were imputed using multiple imputation by chained 
equation (MICE), which assumes data are missing at random11. 
The effect of missing data was explored using both mean and 
multiple imputation. Missing cost values were imputed at the 
aggregate total cost level and missing quality of life data were 
replaced at utility score level at each EQ-5D-3L follow-up 
point using multiple imputation.
The regression analyses used to impute missing data included 
the same explanatory variables used in the missing data 
imputation in the clinical analysis8.
Assumptions
The following additional assumptions were made:
• As intervention resource use was not separately 
identified we have treated all resource use in the first 
6-week period after randomisation as intervention 
resource use.
• The cost of a line insertion and removal was applied 
to the initial 6-week period of the intervention. In 
addition, it was assumed that an intravenous episode 
with a gap of two days or less between intravenous 
drugs did not require a new line to be inserted and a 
cost was not applied for insertion/removal. If the gap 
between episodes was greater than two days, it was 
assumed that a new line had to be inserted and the old 
line was removed, and a cost was assigned accordingly.
• The OPAT type recorded at the 42-day follow-up 
visit was used for each participant for all intravenous 
episodes in the 12-month follow-up period.
• Durations of antibiotics, intravenous episodes and 
inpatient stays per participant were truncated at 365 
days.
• OPAT costs were applied at one hour per day when 
applicable.
• Where participants had an OPAT type of ‘inpatient’ 
and their intravenous episode extended beyond the 
inpatient stay, a weighted average cost of 2/5 Self- 
Administrating and 3/5 District Nurse was applied to the 
length of intravenous episode following discharge from 
hospital, this was the proportion of District Nurse to 
self-administering OPAT witnessed in the trial. The 
same weighted average was applied to participants with 
missing OPAT type.
Table 1. Unit costs and sources.
Resource Unit cost Source
Antibiotic Various British National Formulary12
Inpatient stay £295.80/overnight stay NHS reference costs13
Intravenous administration
        Insertion: PICC1 £190 Expert opinion
        Removal £34.00 Expert opinion
OPAT type
        District nurse £58 per hour NHS reference costs13
        Inpatient (Hospital infusion centre) £109 per hour NHS reference costs13
1Only 6 patients were reported to have a Hickman line inserted and the majority of patients had a PICC line. To 
be consistent within the IV arm, we assumed a constant cost for a PICC line for all patients. A Hickman line is 
likely to increase costs only marginally in the IV arm as these lines involve a surgeon’s time to be inserted.
OPAT, outpatient parenteral antimicrobial therapy.
Page 4 of 16
Wellcome Open Research 2019, 4:108 Last updated: 12 AUG 2019
Data analysis
The base-case analysis used an intention to treat approach 
conducted on the multiple imputed dataset. Total mean costs, 
QALYs and associated standard errors were presented as well as 
the difference in total mean costs and QALYs between arms and 
a 95% confidence interval. An incremental cost-effectiveness 
ratio (ICER) is also presented; representing the difference 
in costs divided by the difference in QALYs.
To explore the uncertainty around the cost and QALY differ-
ences and the resulting ICER, a non-parametric bootstrapping 
technique was employed with 1,000 iterations. Results are 
presented using a cost-effectiveness plane, showing all 1,000 
cost-effectiveness pairs.
The analysis was conducted using Stata version 14 (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, 
TX: StataCorp LP.)
Sensitivity analysis
Four sensitivity analyses were conducted: complete case analy-
sis, mean imputation and two different assumptions for OPAT 
costs. Instead of using the above weighted average for partici-
pants with missing OPAT type, two scenarios were explored by 
varying the OPAT cost: applying solely the cost of a District 
Nurse, and applying solely the cost of Self-Administration.
Ethical approval
Research Ethics Committee Ref: 13/SC/0016 South Central 
Oxford REC B. Written informed consent was obtained from 
each participant by good clinical practice-trained research staff 
after assessing their understanding of the patient information 
sheet.
Results
Baseline characteristics are presented in Table 2. The participants 
were well matched with no significant differences.
A total of 1,054 participants were recruited between June 2010 
and October 2015; 527 in each arm, with 39 having no 
end-point data. In total, 23 participants died during the trial. 
Clinical results from the trial indicate that oral antibiotics are 
non-inferior to intravenous antibiotics with regards to defini-
tive treatment failure. Treatment failure occurred in 74 of 506 
participants (14.6%) in the intravenous arm and in 67 of 509 
participants (13.2%) in the oral arm. The difference in risk, oral 
(PO) compared to intravenous (IV), of definitive failure in the 
intention-to-treat analysis was -1.4 percentage points (95% 
confidence interval, -5.6 to 2.9). These results were mirrored in 
the complete case intention-to-treat population, the per-protocol 
analysis (at least 4 weeks of randomised treatment received) 
and worst-case scenario analysis. These results are presented 
in more detail in the clinical trial paper8.
Resource use
Only 26 participants (2.5%) had missing resource use data; 
12 in the intravenous arm and 14 in the oral arm. The results 
for complete case resource use are presented in Table 3, split 
between resources used in the initial 42-day intervention period 
and the remaining post-intervention period.
Table 2. Baseline characteristics of participants.
Characteristic Intravenous 
(n=527)
Oral 
(n=527)
Total 
(n=1054)
Age, years
Median (interquartile range) 61 (49–70) 60 (49–70) 60 (49–70)
Range 18–92 18–91 18–92
Sex
Male, number (%) 320 (60.7) 358 (67.9) 678 (64.3)
Baseline surgical procedure, number (%)
No implant or device present; debridement of 
chronic osteomyelitis performed
153 (29.0) 169 (32.1) 322 (30.6)
No implant or device present; debridement of 
chronic osteomyelitis not performed
25 (4.7) 29 (5.5) 54 (5.1)
Debridement and implant retention 124 (23.5) 123 (23.3) 247 (23.4)
Removal of orthopaedic device for infection 89 (16.9) 78 (14.8) 167 (15.8)
Prosthetic joint implant removed 68 (12.9) 67 (12.7) 135 (12.8)
Prosthetic joint implant, one-stage revision 47 (8.9) 43 (8.2) 90 (8.5)
Surgery for discitis, spinal osteomyelitis, or epidural 
abscess; debridement performed
8 (1.5) 5 (0.9) 13 (1.2)
Surgery for discitis, spinal osteomyelitis, or epidural 
abscess; debridement not performed
13 (2.5) 13 (2.5) 26 (2.5)
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From the results in Table 3, it can be seen that for interven-
tion resource use there was a statistically significant difference 
between arms in mean antibiotic and intravenous therapy dura-
tion. There were no statistically significant differences between 
arms in mean number of antibiotic prescriptions, number of 
inpatient admissions or inpatient duration. For resource use dur-
ing the post-intervention period there was only a statistically 
significant difference between arms for intravenous therapy 
duration. This is mirrored at a total level where the only statisti-
cally significant difference between arms was for intravenous 
therapy; the mean total number of days for which intravenous 
therapy was received was 34.62 days longer in the intravenous 
arm. Table 4 presents the mean costs in both arms for unadjusted 
complete cases.
The difference between arms in mean antibiotic and intravenous 
costs was statistically significant for intervention, post-intervention 
and total costs. However, there was only a statistically signifi-
cant difference in mean total intervention costs, not for total 
post-intervention costs, £2,215 (95% CI £1,462 to £2,969) and 
£511 (95% CI -£343 to £1,366), respectively. This smaller and 
non-significant difference in total post-intervention costs is 
mainly due to lower intravenous costs after the initial 6-week 
intervention period.
The total mean cost combining intervention and non-intervention 
costs was £13,275 in the intravenous arm compared to £10,549 
in the oral arm, a difference of £2,727, a statistically significant 
result.
Table 3. Mean resource use per participant (complete case).
Resource type Intravenous Oral
Mean (SD) 
N=515 (97.7%)
Mean (SD) 
N=513 
(97.3%)
Difference 95% confidence interval
Intervention period
Number of antibiotic prescriptions 3.53 (2.15) 3.53 (2.31) 0.002 -0.271 to 0.275
Antibiotic duration (days) *† 38.18 (32.64) 30.47 (29.12) 7.71 3.92 to 11.49
Number of inpatient admissions 1 (0) 1 (0) 0 N/A
Inpatient duration (days) 17.71 (14.83) 17.22 (18.62) 0.492 -1.57 to 2.55
Total number of days IV therapy was 
received*†
40.08 (30.52) 11.86 (27.45) 28.22 24.66 to 31.77
Post-intervention period
Number of antibiotic prescriptions 3.17 (3.08) 2.90 (3.00) 0.274 -0.098 to 0.647
Antibiotic duration (days) 151.6 (181.6) 155.1 (161.2) -3.53 -24.54 to 17.48
Number of inpatient admissions 0.829 (1.15) 0.821 (1.11) 0.008 -0.130 to 0.147
Inpatient duration (days) 8.51 (16.78) 9.13 (18.11) -0.618 -2.76 to 1.52
Total number of days IV therapy was 
received
12.50 (34.83) 6.10 (18.49) 6.40 2.99 to 9.81
Total
Number of antibiotic prescriptions 6.70 (3.74) 6.43 (3.93) 0.276 -0.194 to 0.746
Antibiotic duration (days) 189.8 (177.5) 185.6 (156.3) 4.18 -16.29 to 24.65
Number of inpatient admissions 1.83 (1.15) 1.82 (1.11) 0.01 -0.129 to 0.147
Inpatient duration (days) 26.22 (24.28) 26.35 (28.47) -0.125 -3.36 to 3.11
Total number of days IV therapy was 
received
52.58 (40.37) 17.96 (33.52) 34.62 30.08 to 39.16
*The antibiotic duration sums the duration of all antibiotic use, including simultaneous use. For example, if a patient was on two 
different antibiotics for a period of five days, this would add to a duration of ten days. Intravenous duration includes the length 
of intravenous episodes where an intravenous line was needed to administer intravenous antibiotics (including more than one 
intravenous antibiotic taken at the same time as another).
†Antibiotic and IV therapy in the intervention period was not readily available from the data, the duration of these therapies were 
calculated by including all therapies finishing on or within 42 days of the start of first therapy treatment.
SD, standard deviation; IV, intravenous
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An exploratory analysis estimating mean costs for intravenous 
and oral antibiotics for a 42-day course out with the intention 
to treat population was conducted. The mean cost of a 6-week 
course of antibiotics (drug only) was £997 (SD £873) for intra-
venous antibiotics and £188 (SD £648) for oral antibiotics, 
highlighting the higher costs for intravenous drugs.
Multiple imputation results are provided in Table 5. These 
results reflect the complete case results presented above (a 
difference of £2,727), with intravenous mean costs £2,740 
higher than in the oral arm, statistically significant.
Health outcomes: QALYs
The utility values and missing data proportions for each 
follow-up point for the EQ-5D-3L questionnaire are presented in 
Table 6. The proportion of missing data is similar in both arms. 
Participants in the oral antibiotic arm started from a slightly 
higher utility at baseline; 0.330 (SD 0.379) compared to 0.298 
(SD 0.363). At the 14-day follow-up the mean utility was higher 
in the intravenous arm compared to the oral antibiotics arm; 
0.437 (SD 0.304) compared to 0.421 (SD 0.338). The mean 
utilities for the remainder of the follow-up points revert to being 
higher in the oral arm. There were no statistically significant 
differences in mean utilities at any follow-up point. The utili-
ties in both arms improved at each follow-up point compared to 
the previous one.
The mean EQ-5D-3L utilities, along with 95% confidence 
intervals are presented in Figure 1.
Complete case QALYs for each follow-up point and overall 
are provided in Table 7. Results mirror those of the utilities 
with no statistically significant differences between arms at any 
follow-up point; intravenous 0.558 (SD 0.265) compared to 
oral 0.535 (SD 0.300). Results consider a zero-utility score for 
participants who died during the trial.
Table 4. Unadjusted costs (complete case).
Cost category Intravenous Oral
Mean (SD) 
N=515 
(97.7%)
Mean (SD) 
N=513 
(97.3%)
Difference 95% confidence interval
Intervention period
Antibiotics £786 (£915) £435 (£569) £351 £257 to £443
Inpatient stays £5,239 
(£4,388)
£5,093 
(£5,508)
£146 -£464 to £755
Intravenous costs £2,950 
(£2,555)
£1,231 
(£1,304
£1,719 £1,471 to £1,968
Total intervention costs £8,974 
(£6,114)
£6,759 
(£6,196)
£2,215 £1,462 to £2,969
Post-intervention period
Antibiotics £1,206 
(£2,497)
£772 
(£1,865)
£434 £164 to £704
Inpatient stays £2,517 
(£4,963)
£2,700 
(£5,358)
-£183 -£815 to £449
Intravenous costs £577 
(£1,566)
£318 
(£801)
£259 £107 to £412
Total non-intervention £4,301 
(£7,060)
£3,790 
(£6,899)
£511 -£343 to £1,366
Total
Antibiotics £1,992 
(£2,545)
£1,207 
(£2,043)
£785 £502 to £1,067
Inpatient stays £7,756 
(£7,183)
£7,793 
(£8,420)
-£37 -£995 to £920
Intravenous costs £3,527 
(£2,920)
£1,548 
(£1,618)
£1,979 £1,690 to £2,268
Total costs £13,275 (£10,113) £10,549 (10,371) £2,727 £1,473 to £3,980
SD, standard deviation.
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Table 5. Multiple imputation results - total mean costs.
Intravenous mean cost (SD) Oral mean cost (SD) Difference 
(95% confidence interval)
£13,274 (£446) £10,534 (£453) £2,740 (£1,488 to £3,992)
SD, standard deviation.
Table 6. EQ-5D-3L complete cases.
Utilities Intravenous Oral
Mean (SD) N (%) Mean (SD) N (%) Difference (SE) 95% 
confidence 
interval
Baseline 0.298 
(0.363)
386 
(73.2%)
0.330 
(0.379)
388 
(73.6%)
-0.032 
(0.027)
-0.085 to 0.020
14 days 0.437 
(0.304)
308 
(58.4%)
0.421 
(0.338)
309 
(58.6%)
0.016 
(0.026)
-0.035 to 0.067
42 days 0.513 
(0.316)
366 
(69.4%)
0.531 
(0.330)
374 
(71.0%)
-0.018 
(0.024)
-0.064 to 0.029
120 days 0.534 
(0.337)
312 
(59.2%)
0.544 
(0.354)
306 
(58.1%)
-0.011 
(0.028)
-0.065 to 0.044
365 days 0.564 
(0.339)
301 
(57.1%)
0.576 
(0.346)
286 
(54.3%)
-0.016 
(0.028)
-0.067 to 0.044
SD, standard deviation; N, number; SE, standard error.
Figure 1. Complete case mean EQ-5D-3L utilities at baseline and follow-ups, with 95% confidence intervals.
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A post-hoc regression of QALYs on ‘definite failure’ was con-
ducted; the indicator variable for failure was found to be 
statistically significant, confirming that the EQ-5D-3L measure 
is sensitive to the endpoint, however the endpoint was found not 
to differ between arms.
Multiple imputation results are provided in Table 8. These 
reflect the complete case results; there is no statistically signifi-
cant difference in QALYs; however, the results now favour the 
oral arm.
Cost-effectiveness analysis
In the incremental analysis (Table 9) base-case mean costs 
were observed to be lower in the oral arm and mean QALYs were 
higher in the oral arm, suggesting that the strategy of treating 
bone and joint infections with oral antibiotics is a dominant 
strategy (cheaper and with higher QALYs). The results of the 
sensitivity analyses indicate that the base-case conclusions were 
robust. Results for complete case, using mean imputation and 
altering the costs of OPAT were all consistent with the results 
from the base-case analysis; the total mean cost difference for 
all scenarios were within the range of £2,617 to £2,887. All of 
these results showed a statistically significant difference between 
arms. The results of multiple imputation and complete case 
QALYs show no statistically significant differences between 
arms. Uncertainty surrounding this result is explored further in 
the next section.
Uncertainty
The main uncertainty in the results relates to QALYs; the 
difference in QALYs between arms is not statistically significant.
The cost-effectiveness plane presented in Figure 2, shows 
1,000 bootstrap samples of the ICER, along with a point esti-
mate illustrating the mean differences in costs and QALYs 
between treatment arms. The graph also includes the lower and 
upper 95% confidence interval from the bootstrap samples, and 
a line illustrating the £30,000 threshold currently used by NICE 
to assess cost-effectiveness9. All bootstrap samples had a lower 
cost in the oral arm compared to the intravenous arm, and the 
majority (82.8%) of cost-effectiveness pairs fall into the south-
east quadrant, where higher QALYs and lower costs can be 
observed for the oral arm as compared with the intravenous 
arm, making an oral intervention dominant for these samples. A 
small number of samples fall into the south-west quadrant of the 
plane where patients in the oral arm have less QALYs than 
patients in the intravenous arm.
Discussion
Statement of principal findings
The difference in costs between arms was £2,740 in the base 
case results; the use of oral antibiotics in the early treatment 
of bone or joint infection is significantly cheaper compared to 
the use of intravenous antibiotics. The results of the EQ-5D-3L 
questionnaires reflected the trial primary outcome of definitive 
failures; there was no statistically significant difference in QALYs 
between arms. This is reinforced by the post-hoc regression of 
QALYs on ‘definite failure’, which confirmed that the EQ-5D-
3L measure is sensitive to the endpoint, but the endpoint did not 
differ between arms. With oral antibiotics being clinically non-
inferior to intravenous, no statistically significant difference 
in QALYs plus the costs in the oral arm being significantly less 
than in the intravenous arm during the trial, the results of the 
trial suggest that treating patients with bone and joint infections 
with oral antibiotics is a dominant strategy.
There was no statistically significant difference in antibiotic 
duration in the post-intervention period suggesting that partici-
pants in the oral arm were not prescribed more antibiotics once 
finished on the intervention antibiotic. This is reflected by 
the difference between arms in the number of antibiotic prescrip-
tions during the post intervention period not being statistically 
Table 7. Quality adjusted life-years complete cases.
Quality-adjusted 
life years
Intravenous Oral
Mean (SD) N (%) Mean (SD) N (%) Difference (SE) 95% confidence 
interval
14 days 0.014 
(0.011)
297 
(56.3%)
0.014 
(0.012)
300 
(56.9%)
-0.0001 
(0.0009)
-0.0020 to 0.0017)
42 days 0.037 
(0.022)
265 
(50.3%)
0.037 
(0.023)
274 
(52.0)
-0.0002 
(0.0019)
-0.0039 to 0.0036
120 days 0.111 
(0.063)
280 
(53.1%)
0.116 
(0.064)
279 
(52.9%)
-0.0045 
(0.0054)
-0.0150 to 0.0060
365 days 0.365 
(0.200)
224 
(46.3%)
0.365 
(0.213)
228 
(43.3)
-0.0003 
(0.0191)
-0.0378 to 0.0372
Total year 0.558 
(0.265)
179 
(34.0%)
0.535 
(0.300)
182 
(31.8%)
0.023 
(0.030)
-0.036 to 0.081
SD, standard deviation; SE, standard error.
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Table 9. Incremental cost-effectiveness results.
Analysis Intravenous 
Mean costs 
(SE)
Oral 
Mean 
costs (SE)
Difference (95% 
confidence 
interval)
Intravenous 
Mean QALYs 
(SE)
Oral Mean 
QALYs 
(SE)
Difference (95% 
confidence 
interval)
Incremental 
cost per QALY
Base case (Multiple 
imputation)
£13,274 
(£446)
£10,534 
(£453)
£2,740 
(£1,488 to £3,992)
0.537 
(0.013)
0.545 
(0.015)
-0.007 
(-0.045 to 0.031)
Oral antibiotics 
dominant
Complete case £13,275 
(£10,113)
£10,549 
(10,371)
£2,727 
(£1,473 to £3,980)
0.558 
(0.265)
0.535 
(0.300)
0.023 
(–0.036 to 0.081)
Oral antibiotics 
dominant
Mean imputation 
costs
£13,141 
(£10,036)
£10,406 
(£10,269)
£2,735 
(£1,508 to £3,963)
0.537 
(0.013)
0.545 
(0.015)
-0.007 
(-0.045 to 0.031)
Oral antibiotics 
dominant
District Nurse costs 
for all missing OPAT 
types
£13,274 
(£448)
£10,657 
(£463)
£2,617 
(£1,354 to £3,880)
0.537 
(0.013)
0.545 
(0.015)
-0.007 
(-0.045 to 0.031)
Oral antibiotics 
dominant
Self-administration 
costs for all missing 
OPAT types
£13,230 
(£442)
£10,343 
(£448)
£2,887 
(£1,656 to £4,118)
0.537 
(0.013)
0.545 
(0.015)
-0.007 
(-0.045 to 0.031)
Oral antibiotics 
dominant
QALYs, quality-adjusted life years; SE, standard error; OPAT, outpatient parenteral antimicrobial therapy.
Table 8. Multiple imputation results – total mean quality-adjusted life years (QALYs).
Intravenous mean QALYs (SE) Oral mean QALYs (SE) Difference (95% confidence interval)
0.537 
(0.013)
0.545 
(0.015)
-0.007 
(-0.045 to 0.031)
SE, standard error
Figure 2. Cost-effectiveness plane.
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significant. As expected, the mean number of days that intrave-
nous therapy was received during the intervention period was 
significantly higher in the intravenous arm; 28.22 days (95% 
confidence interval 24.66 to 31.77). Interestingly there was a sig-
nificant difference in the post-intervention period also; 6.40 days 
(95% confidence interval 2.99 to 9.81). We found no signifi-
cant difference in mean inpatient stay duration; however, there 
was a significant difference for median inpatient stay duration; 
14 days (interquartile range 11 to 21) in the intravenous arm and 
11 days (interquartile range 8 to 20) in the oral arm (p<0.001)8.
Exploring uncertainty in the results using non-parametric 
bootstrapping estimates that in 82.8% of the bootstrap samples 
the oral strategy is dominant, and in 17.2% of the samples the 
intravenous strategy would result in higher QALYs than the 
oral strategy; however, still at a higher cost. There is 100% prob-
ability that the oral strategy saves money and no indication of 
superiority of the intravenous strategy on QALYS plus prior 
evidence of clinical non-inferiority. Results from sensitivity 
analyses results were consistent with the base case results.
Strengths and limitations of the research
This is the first economic evaluation of oral versus intravenous 
antibiotics for treating bone and joint infections. The trial was a 
large inclusive, pragmatic trial with most participants following 
their allocated treatment and retention was high8.
Some of the limitations arose from the high level of missing 
data for the EQ-5D-3L questionnaire (from 26.4% at baseline to 
45.7% at 365-days). No costs of surgery for treatment of bone 
and joint infections were included in this study; this was a pre- 
randomisation procedure.
Strengths and weaknesses in relation to other studies, 
discussing important differences in results
Despite the high economic burden of bone and joint infections, 
economic studies in this area are rare22 and there is a need for 
more economic evaluations of joint infections23. No previous 
studies have explored the cost-effectiveness of oral antibiotics 
to treat bone and joint infections compared to oral antibiotics. 
A cost-effectiveness study, comparing exchange arthroplasty 
with debridement and prosthetic retention for infected total hip 
arthroplasty in the elderly, found debridement and retention 
improved quality-adjusted life expectancy and increased costs 
in 65- and 80-year-old men and women over a lifetime24. The 
incremental cost-effectiveness ratio ranged from $500 for frail 
80 year old men to $21,800 in 65 year old women. In an eco-
nomic evaluation by Kapadia et al., the authors explored the 
use of chlorhexidine cloths prior to total knee arthroplasty and 
found that assuming 1,000 total knee arthroplasty patients a 
net saving of $2.1 million would occur25. The study assumed an 
estimated cost of $130,000 per revision due to infection, with 
22 patients in a cohort of 1,000 without use of the cloth 
becoming infected, and 6 infections in the cohort using the 
cloth. Two studies estimated revision costs for infected 
prostheses; for infected hips, estimated costs are £22,0004 and 
for infected knees, £30,0005. These costs included the revision 
surgery and subsequent inpatient stay. A 2013 review summarised 
the economic literature in the treatment of periprosthetic infec-
tions, looking at prevention, treatment and surgical options for 
periprosthetic infections26. Unlike OVIVA, the treatment costs 
included the cost of revision and a 1993 study estimated an 
average cost of $50,000 to $60,000 per patient with an infected 
total hip arthroplasty22.
Meaning of the study
Annually in the UK, it is conservatively estimated that there are 
6,350 post-operative bone and joint infections; if all of these 
were treated with oral antibiotics during the first six weeks of 
therapy there is a potential for savings to the NHS of around 
£17 million annually. The important non-financial benefits to 
patients receiving oral antibiotics include a shorter median 
inpatient stay as well as decreased indwelling intravenous cath-
eter days with its associated inconvenience, discomfort and 
reduced complications. Ultimately, the savings made by the use of 
oral antibiotics in half of the trial participants have already 
exceeded the running costs of the clinical trial.
Unanswered questions and future research
Further savings in the management of bone and joint infection 
might be possible by defining the optimal duration of therapy. 
At present, there are few trial data to guide duration and, in the 
opinion of the authors, there may be considerable redundancy in 
current standard treatment protocols. The benefits of limiting 
systemic antimicrobial exposure may well include a reduction in 
selection for antibiotic resistance and a consequent cost saving 
in managing treatment failures or transmission events.
What is already known on this topic:
• The ‘gold standard’ treatment for bone and joint 
infections is surgery followed by a course of 
intravenous antibiotics
• There is a growing body of literature showing that oral 
antibiotics are as effective as intravenous in treating 
this cohort
• Oral antibiotics are less costly than intravenous 
antibiotics
What this study adds:
• Oral antibiotics are non-inferior compared to 
intravenous antibiotics in treating bone and joint 
antibiotics with regards to definitive treatment failure
• Treating a bone or joint infection with an initial 6 
weeks course of oral antibiotics saves an estimated 
£2,700 over one year, per person, compared to early 
treatment with intravenous antibiotics
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Data availability
Underlying data
The ethical permissions governing this trial limit data shar-
ing to approved studies of antibiotic treatment. Requests for 
participant level data should be directed to the chief investigator; 
Dr Matthew Scarborough (email address: Matthew.Scarborough@
ouh.nhs.uk). Requests from interested parties will be granted 
access to the data when there is appropriate approval from their 
home institution for their analysis and where the purpose of the 
proposed analysis relates to antibiotic treatment, consistent with 
our ethical approval for sharing data
Reporting guidelines
Figshare: CHEERS checklist for “Cost-effectiveness of oral 
versus intravenous antibiotics (OVIVA) in patients with bone 
and joint infection: evidence from a non-inferiority trial”. https://
doi.org/10.6084/m9.figshare.8197682.v127.
The completed CHEERS checklist is available under the terms 
of the Creative Commons Attribution 4.0 International license (CC-
BY 4.0).
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General comment
The work is undertaken to a high standard, is clearly written and produces robust conclusions. The
research is very important.
Some relatively minor details are omitted and need to be added.  Some methods deviate from the
‘standard approach’, and as such, need to be justified more clearly.
 
Specific comments
An undefined personal communication is used for an important estimate. Either something should
be said about its source (e.g. opinion or audit) or a published estimate should be used [first
paragraph, p3].
 
“Missing resource and quality of life data was imputed….”, should be “…were imputed” [middle
paragraph, second column, p3].
 
More should be said in the Introduction or Methods about how IV and oral antibiotics are
administered and the role of the OPAT team. This is important for readers to assess the
generalisability of findings. It is also unclear how you can have an “inpatient” OPAT type [p4]; I
thought OPAT was outpatient.
 
“…an appropriate method to replace missing data utilised”. On what basis was appropriateness
assessed? Just giving a reference is insufficient. Also, I would have thought that Reference 11
would have been used for this assessment, but it is not referenced at this point. [p4]
 
In Table 1, simply saying that “insertion” and “Removal” costs were based on expert opinion is
insufficient. Presumably, the experts didn’t come up with the cost; they provided timings, staff
grades and consumables, which were then costed up. Those resource estimates should be
provided, possibly as notes to the table. [p4]
 
It is stated that QALYs were adjusted for baseline utility, but not how this was done; providing a
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It is stated that QALYs were adjusted for baseline utility, but not how this was done; providing a
reference is insufficient. If this was done statistically, which is implied by the reference, how did you
then generate the bootstrapped estimates? [p4]
 
The statistical tests used to compare groups in all the tables are not described. These need to be
justified.
 
The inpatient duration for oral therapy is almost identical to that for IV. An explanation of this needs
to be given. A lay reader may equate oral therapy to home treatment and IV therapy to inpatient
treatment, therefore inpatient duration may be expected to be similar to number of days of IV
therapy. [p6]
 
The sentence starting “Table 4 presents….” should be the first sentence of the next paragraph.
 
An exploratory analysis appears in the middle of the results, would this be better framed as a
sensitivity analysis? The way it is presented suggest that it is unplanned/post-hoc.
 
Is Table 5 necessary? The results are given in the text anyway (except for the estimates of
variation, which could be added). [p8]
 
The post-hoc regression of QALYs on failure is not a result; it should be part of the discussion
about the perceived weakness of the EQ-5D for this condition/study. [p9]
 
The description of the bootstrapped replications in cost-effectiveness plane on [p9] and [p11] don’t
seem to match the figure, for example 82.8% fall into the south east quadrant. Do you mean, fall to
right of the cost-effectiveness threshold line? You also say that 17.2% of the sample result in
higher QALYs, really?
 
The threshold line in the SE quadrant is not necessary. [p10]
 
The statement starting “There is a 100% probability that...” includes an ‘and statement’ which
makes interpretation confusing/difficult. This needs to be re-written. You may also want to consider
qualifying the statement by saying that it relates to this particular set of bootstrapped samples,
another set may produce a lower probability. [p11]
 
Something needs to be said about covariate adjustment within the economics analysis. Whilst an
adjustment has been made for baseline utility (but not described sufficiently), it is common in
economic evaluation for other covariates to be included in a regression based analysis, sometimes
in the form of a related regression on QALYs. Whilst I don’t consider this to be a big issue in this
instance, the authors should describe this alternative approach and explain the appropriateness
their approach, this is methodological uncertainty.
 
Something needs to be said about the truncation of data. Alternative methods would be to take
account of this within a regression analysis of costs and QALYs using appropriate specifications,
or to extrapolate the costs/QALYs. Again, whilst I don’t consider this to be a big issue in this
instance, the authors should describe this alternative approach and explain the appropriateness of
their approach, this is methodological uncertainty.
Is the work clearly and accurately presented and does it cite the current literature?
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